10x Genomics Financial Ratios
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
80.65+3.37 (+4.36%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
10x Genomics ratio analysis
10x Genomics earned a net margin of -6.8% in FY 2025, up from -29.9% a year earlier. Gross margin was 69.1% compared with a median of 78.5% over the prior 8 years. Return on equity reached -5.5%, meaning 10x Genomics generated -0.05 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
10x Genomics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 3.23 | 3.08 | 10.60 | 8.03 | 33.51 | 47.93 | 12.01 | — | — |
| Price / book | 2.60 | 2.65 | 8.85 | 5.15 | 20.11 | 19.38 | 7.03 | — | — |
| Gross margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Operating margin | -9.5% | -31.9% | -42.9% | -32.5% | -10.7% | -178.7% | -12.4% | -75.7% | -25.8% |
| Net margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% | -12.7% | -76.9% | -26.4% |
| Free cash flow margin | 20.2% | -0.9% | -10.3% | -32.0% | -25.0% | -85.2% | -3.3% | -56.5% | -20.3% |
| Return on equity (ROE) | -5.5% | -25.7% | -34.4% | -20.6% | -7.1% | -73.4% | -7.4% | — | — |
| Return on assets (ROA) | -4.2% | -19.9% | -26.4% | -16.1% | -5.7% | -58.4% | -5.2% | -90.5% | — |
| Debt / equity | — | — | — | — | — | 0.00 | 0.07 | — | — |
| Current ratio | 4.46 | 4.97 | 4.69 | 4.85 | 6.77 | 6.56 | 7.63 | 3.28 | — |
| Revenue growth | 5.2% | -1.3% | 19.8% | 5.3% | 64.1% | 21.5% | 68.1% | 105.8% | — |